Home / Companies / REGN / Catalysts / Page 3 Catalysts · REGN · CIK 872589 · page 3 of 3 REGN catalysts and FDA events, page 3. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on REGN PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source March 8, 2024 Praluent (alirocumab) REGN Label expansion — Approved openFDA Drugs@FDA January 25, 2024 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA January 12, 2024 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA August 18, 2023 Veopoz (pozelimab-bbfg) REGN FDA approval — Approved FDA Novel Drug Approvals August 18, 2023 PAVBLU® (aflibercept) REGN FDA approval — Approved openFDA Drugs@FDA Aug 2023Month disclosed Eylea® REGN FDA approval — Approved SEC 8-K Exhibit 99.1 June 27, 2023 PAVBLU® (aflibercept) REGN Complete Response Letter — CRL issued FDA Complete Response Letters April 28, 2023 Libtayo (cemiplimab-rwlc) REGN Label expansion — Approved openFDA Drugs@FDA March 21, 2023 Evkeeza (evinacumab-dgnb) REGN Label expansion — Approved openFDA Drugs@FDA February 8, 2023 PAVBLU® (aflibercept) REGN Label expansion — Approved openFDA Drugs@FDA November 8, 2022 Libtayo (cemiplimab-rwlc) REGN Label expansion — Approved openFDA Drugs@FDA September 28, 2022 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA June 7, 2022 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA May 20, 2022 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA October 20, 2021 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA June 14, 2021 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA April 1, 2021 Praluent (alirocumab) REGN Label expansion — Approved openFDA Drugs@FDA February 22, 2021 Libtayo (cemiplimab-rwlc) REGN Label expansion — Approved openFDA Drugs@FDA February 11, 2021 Evkeeza (evinacumab-dgnb) REGN FDA approval — Approved openFDA Drugs@FDA February 9, 2021 Libtayo (cemiplimab-rwlc) REGN Label expansion — Approved openFDA Drugs@FDA October 14, 2020 Inmazeb (atoltivimab; maftivimab; odesivimab) REGN FDA approval — Approved openFDA Drugs@FDA June 25, 2020 Libtayo (cemiplimab-rwlc) REGN Label expansion — Approved openFDA Drugs@FDA June 18, 2020 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA May 26, 2020 Dupixent (dupilumab) REGN Label expansion — Approved openFDA Drugs@FDA September 28, 2018 Libtayo (cemiplimab-rwlc) REGN FDA approval — Approved openFDA Drugs@FDA March 28, 2017 Dupixent (dupilumab) REGN FDA approval — Approved openFDA Drugs@FDA
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from REGN’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.